Insmed Affirms 2025 Global Arikayce Revenue Target of $405M-$425M, Below Consensus Estimate of $466.61M

Insmed has reaffirmed its 2025 global Arikayce revenues guidance of $405-425M, which is below the consensus estimate of $466.61M. The company's drug is used to treat nontuberculous mycobacterial (NTM) lung disease.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on delivering first- and best-in-class therapies, has reaffirmed its 2025 global ARIKAYCE revenue guidance of $405 million to $425 million. This range is below the consensus estimate of $466.61 million, reflecting the company's strategic focus on expanding its pipeline and advancing clinical trials [1].

ARIKAYCE, a liposomal amikacin inhalation suspension used to treat nontuberculous mycobacterial (NTM) lung disease, saw a 19% increase in total revenue during the second quarter of 2025 compared to the same period in 2024. This growth was driven by strong performance across all geographic regions, with the U.S. and Japan leading the way. The company expects to achieve a double-digit year-over-year growth rate for ARIKAYCE in 2025, with revenues in the range of $405 million to $425 million [1].

Insmed's reaffirmation of its revenue guidance comes amidst a robust pipeline of clinical trials and regulatory submissions. The company anticipates topline data from its Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps by the end of 2025. Additionally, Insmed plans to initiate Phase 3 studies for TPIP in both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH) in the second half of 2025 and early 2026, respectively [1].

The company's financial results for the second quarter of 2025 reflect a net loss of $321.7 million, primarily due to increased research and development expenses and selling, general, and administrative costs. Insmed continues to invest heavily in its pipeline, with a focus on commercialization and expansion of ARIKAYCE, and the advancement of brensocatib, TPIP, and other clinical development programs [1].

Insmed will host a conference call on August 7, 2025, at 8:00 AM Eastern Time to discuss its second-quarter results and provide an update on its business activities. Shareholders and interested parties can participate in the call by dialing (888) 210-2654 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the company's website at www.insmed.com [1].

References:
[1] Insmed Incorporated. (2025). Insmed reports second-quarter 2025 financial results and provides business update. Retrieved from https://www.prnewswire.com/news-releases/insmed-reports-second-quarter-2025-financial-results-and-provides-business-update-302523543.html